Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Beats Estimates By $0.02 EPS

Heron Therapeutics (NASDAQ:HRTX) issued its earnings results on Monday. The biotechnology company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02, Fidelity Earnings reports. Heron Therapeutics had a negative return on equity of 49.22% and a negative net margin of 194.43%. The company had revenue of $36.66 million for the quarter, compared to analyst estimates of $31.04 million.

Shares of HRTX stock traded down $0.01 on Tuesday, hitting $16.44. 123,693 shares of the stock were exchanged, compared to its average volume of 725,769. The company has a quick ratio of 4.06, a current ratio of 4.40 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -6.74 and a beta of 1.49. Heron Therapeutics has a one year low of $16.03 and a one year high of $41.55. The firm has a 50 day moving average price of $18.15.

A number of research analysts have issued reports on HRTX shares. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. Northland Securities restated a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a research note on Monday. ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Cowen restated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, May 9th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a research note on Monday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Heron Therapeutics has an average rating of “Hold” and an average target price of $48.20.

In related news, Director Waage Christian bought 1,400 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $18.04 per share, for a total transaction of $25,256.00. Following the purchase, the director now directly owns 1,400 shares in the company, valued at $25,256. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Poyhonen bought 3,000 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was bought at an average price of $17.55 per share, with a total value of $52,650.00. Following the purchase, the director now owns 13,000 shares in the company, valued at $228,150. The disclosure for this purchase can be found here. 12.56% of the stock is currently owned by corporate insiders.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Outstanding Shares and The Effect on Share Price

Earnings History for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.